Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Lineage Cell Therapeutics, Inc.LCTX · Entity 6045 | Director | July 01, 2026 | July 02, 2026 |
| Structure Therapeutics Inc.GPCR · Entity 1222 | Director | June 17, 2026 | June 18, 2026 |
| TherapeuticsMD, Inc.TXMD · Entity 7541 | Director | September 29, 2022 | October 03, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Lineage Cell Therapeutics, Inc.
Report date July 01, 2026 · Filed July 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.30 · Expires 2036-07-01 | Direct | 125,000 |
Reported balance
After 2026-07-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-07-01 · Grant · Acquired 125,000 · Balance 125,000 F1: Will vest and become exercisable on the earlier of July 1, 2027 and the date of the issuer's next annual meeting of shareholders, subject in any case to the reporting person's continuous service with the issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: Will vest and become exercisable on the earlier of July 1, 2027 and the date of the issuer's next annual meeting of shareholders, subject in any case to the reporting person's continuous service with the issuer.
Structure Therapeutics Inc.
Report date June 17, 2026 · Filed June 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Share Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.00 · Expires 2036-06-16 | Direct | 39,453 |
Reported balance
After 2026-06-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-17 · Grant · Acquired 39,453 · Balance 39,453 F1: The option exercise price per share is equal to the fair market value per Ordinary Share on the grant date based on the trading price of the Issuer's American Depositary Shares ("ADSs"). F2: The shares vest in equal monthly installments over the 12 months following June 17, 2026, provided that the grant will in any case be fully vested on the date immediately prior to the date of the Issuer's 2027 annual shareholder meeting, F3: The Ordinary Shares of the Issuer may be represented by ADSs. Each ADS represents three Ordinary Shares of the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: The option exercise price per share is equal to the fair market value per Ordinary Share on the grant date based on the trading price of the Issuer's American Depositary Shares ("ADSs").
F2: The shares vest in equal monthly installments over the 12 months following June 17, 2026, provided that the grant will in any case be fully vested on the date immediately prior to the date of the Issuer's 2027 annual shareholder meeting,
F3: The Ordinary Shares of the Issuer may be represented by ADSs. Each ADS represents three Ordinary Shares of the Issuer.
TherapeuticsMD, Inc.
Report date September 29, 2022 · Filed October 03, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 5,000 |
Reported balance
After 2022-09-29 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-09-29 · Grant · Acquired 5,000 · Balance 5,000 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock of the Issuer. The RSU's will vest on September 29, 2023. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock of the Issuer. The RSU's will vest on September 29, 2023.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Keenova Therapeutics plc
Report date June 16, 2022 · Filed June 21, 2022
Section 16 reporting ended · disclosed 2022-06-21. Current position is not established by this disclosure.
No balance rows disclosed in this filing.
Revance Therapeutics, Inc.
Report date February 04, 2025 · Filed February 06, 2025
Section 16 reporting ended · disclosed 2025-02-06. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2025-02-06 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2025-02-04 · Other · Disposed 36,506 · Balance 15,000 F1: The reported securities were disposed of pursuant to the terms of the Amended and Restated Agreement and Plan of Merger, dated as of December 7, 2024 (as subsequently amended, the "Merger Agreement"), by and among the Issuer, Crown Laboratories, Inc., a Delaware corporation ("Parent"), Reba Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Merger Sub," and together with Parent, the "Buyer Parties"), pursuant to which Merger Sub completed a cash tender offer (the "Offer") for all of the issued and outstanding shares of common stock, par value $0.001 per share (the "Shares"), of the Issuer at a purchase price of $3.65 per share, without interest, and subject to any applicable withholding taxes (the "Per Share Price"). These Issuer Shares were tendered for purchase pursuant to the Offer. Row 2 · 2025-02-06 · Disposition to issuer · Disposed 15,000 · Balance 0 F2: Pursuant to the Merger Agreement, each Issuer restricted stock award held by a non-employee member of the Issuer board then outstanding and not vested was canceled and converted into the right to receive the Per Share Price. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported securities were disposed of pursuant to the terms of the Amended and Restated Agreement and Plan of Merger, dated as of December 7, 2024 (as subsequently amended, the "Merger Agreement"), by and among the Issuer, Crown Laboratories, Inc., a Delaware corporation ("Parent"), Reba Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Merger Sub," and together with Parent, the "Buyer Parties"), pursuant to which Merger Sub completed a cash tender offer (the "Offer") for all of the issued and outstanding shares of common stock, par value $0.001 per share (the "Shares"), of the Issuer at a purchase price of $3.65 per share, without interest, and subject to any applicable withholding taxes (the "Per Share Price"). These Issuer Shares were tendered for purchase pursuant to the Offer.
F2: Pursuant to the Merger Agreement, each Issuer restricted stock award held by a non-employee member of the Issuer board then outstanding and not vested was canceled and converted into the right to receive the Per Share Price.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 01, 2018 Filed Mar 5, 2018 21:34 UTC | Keenova Therapeutics plc MNK · Entity 28960 | Tax withholdingOrdinary Shares | 2,576 | $15.68 | $40,391.68 |
DisclosureSEC source: 0000950138-18-000216 · edgar.xml · nonDerivative · entry 1 Russell Angus C. · CIK 0001534002 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,695 Read SEC document |
| October 01, 2017 Filed Oct 3, 2017 21:10 UTC | Keenova Therapeutics plc MNK · Entity 28960 | Tax withholdingOrdinary Shares | 476 | $37.37 | $17,788.12 |
DisclosureSEC source: 0000950138-17-000706 · edgar.xml · nonDerivative · entry 1 Russell Angus C. · CIK 0001534002 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,271 Read SEC document |
| July 01, 2017 Filed Jul 5, 2017 23:52 UTC | Lineage Cell Therapeutics, Inc. BTX · Entity 6045 | GrantOption to Purchase Common Shares · Derivative | 20,000 | $0.00 Strike: $3.15 | $0.00 |
DisclosureSEC source: 0001209191-17-043781 · doc4.xml · derivative · entry 2 Russell Angus C. · CIK 0001534002 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Shares · 20,000 shares Expires 2022-06-30 F1 · derivative.exercise_date: Will become exercisable in four equal quarterly installments after the date of grant on July 1, 2017 based upon continued service on the board of directors. Read SEC document |
| June 21, 2017 Filed Jun 23, 2017 20:31 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $5.80 | $0.00 |
DisclosureSEC source: 0001387131-17-003413 · russell-form4_062117.xml · derivative · entry 1 Russell Angus C. · CIK 0001534002 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2027-06-21 Read SEC document |
| May 11, 2017 Filed May 12, 2017 19:44 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | GrantStock Option (Right to Buy) · Derivative | 6,000 | $0.00 Strike: $20.90 | $0.00 |
DisclosureSEC source: 0001209191-17-032202 · doc4.xml · derivative · entry 2 Russell Angus C. · CIK 0001534002 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 6,000 shares Expires 2027-05-10 F2 · derivative.exercise_date: The shares subject to the stock option shall vest on the one year anniversary, May 11, 2018, subject to Mr. Russell's Continuous Service (as defined in the Plan) through such vesting date. The stock option represents an annual option grant pursuant to the Compensation Policy. Read SEC document |
| May 11, 2017 Filed May 12, 2017 19:44 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | GrantCommon Stock | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-032202 · doc4.xml · nonDerivative · entry 1 Russell Angus C. · CIK 0001534002 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 F1 · shares: Represents an annual restricted stock award (the "RSA") granted pursuant to the Issuer's Amended and Restated Non-Employee Director Compensation Policy (the "Compensation Policy"). The shares underlying the RSA shall vest on the one year anniversary, May 11, 2018, subject to Mr. Russell's Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan (the "Plan")) through such vesting date. Read SEC document |
| March 01, 2017 Filed Mar 3, 2017 23:44 UTC | Keenova Therapeutics plc MNK · Entity 28960 | Tax withholdingOrdinary Shares | 2,286 | $51.55 | $117,843.30 |
DisclosureSEC source: 0000950138-17-000263 · edgar.xml · nonDerivative · entry 2 Russell Angus C. · CIK 0001534002 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,747 Read SEC document |
| March 01, 2017 Filed Mar 3, 2017 23:44 UTC | Keenova Therapeutics plc MNK · Entity 28960 | GrantOrdinary Shares | 5,723 | $0.00 | $0.00 |
DisclosureSEC source: 0000950138-17-000263 · edgar.xml · nonDerivative · entry 1 Russell Angus C. · CIK 0001534002 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,033 F1 · shares: Consists of restricted stock units that vest in their entirety as of March 1, 2018. The restricted stock units settle in ordinary shares upon vesting. Read SEC document |
| December 21, 2016 Filed Dec 23, 2016 00:13 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $5.68 | $0.00 |
DisclosureSEC source: 0001387131-16-008710 · russell-form4_12212016.xml · derivative · entry 1 Russell Angus C. · CIK 0001534002 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2026-12-20 Read SEC document |
| October 01, 2016 Filed Oct 4, 2016 13:06 UTC | Keenova Therapeutics plc MNK · Entity 28960 | GrantOrdinary Shares | 1,057 | $0.00 | $0.00 |
DisclosureSEC source: 0000950138-16-001375 · edgar.xml · nonDerivative · entry 1 Russell Angus C. · CIK 0001534002 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,310 F1 · shares: Consists of restricted stock units that vest in their entirety as of October 1, 2017. The restricted stock units settle in ordinary shares upon vesting. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.